Alvogen certainly stood out in the crowd at the Cphi in Paris last week and came home with two glistening prizes from the Global Generics & Biosimilars Awards 2014 held on 7 October: the Company of the Year-Americas Award and the Business Development of the Year Award.
“This is a great honour,” Robert Wessman commented, “we are truly grateful for this recognition. We owe this achievement to all the hard work put in by our expanding Alvogen team around the globe.”
Co-hosted by Generics bulletin and Ark Patent Intelligence, the Global Generics & Biosimilars Awards recognise the best in the global generics and biosimilars industries. More than 150 invited guests – including several CEOs and other senior managers – from the industries’ leading players gathered to network and celebrate at an evening cocktail and canapés Awards ceremony.
Based on company submissions and nominations, expert independent judges voted for winners in 11 categories. The Awards, which are sponsored by Generics bulletin recognised Alvogen’s rapid growth in North America and its licensing deal in Central and Eastern Europe for Hospira’s Inflectra (infliximab) biosimilar. Alvogen’s Executive Chairman and CEO Robert Wessman was delighted to step on the stage to pick up the prizes. William Hill and Lisa Graver lead Alvogen business in the US.